Relevant bibliographies by topics / Monoclonal antibodies ; Immunotherapy

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Monoclonal antibodies ; Immunotherapy'

Author: Grafiati
Published: 4 June 2021
Last updated: 12 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Monoclonal antibodies ; Immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Monoclonal antibodies ; Immunotherapy"

1

Jefferis, Roy. "Monoclonal antibodies in immunotherapy." Journal of Prescribing Practice 1, no. 1 (2019): 26–31. http://dx.doi.org/10.12968/jprp.2019.1.1.26.

Full text
Abstract:
The bench-to-bedside ideal is being realised for both humoral and cellular immunotherapy. Monoclonal antibodies (mAbs) are established in the clinic, but continuous development has resulted in progression from mouse/human chimeric to humanised, ‘fully’ human, antibody–drug conjugates, biosimilars and biobetter therapeutics. The objective has been to minimise their potential for immunogenicity and to elucidate and exploit their multiple mechanisms of action (MoA). However, exploitation of these advances within the NHS is limited due their high cost. Consequently, the National Institute for Heal
APA, Harvard, Vancouver, ISO, and other styles
2

Weiner, Louis M., Madhav V. Dhodapkar, and Soldano Ferrone. "Monoclonal antibodies for cancer immunotherapy." Lancet 373, no. 9668 (2009): 1033–40. http://dx.doi.org/10.1016/s0140-6736(09)60251-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Reisfeld, Ralph A. "Monoclonal Antibodies in Cancer Immunotherapy." Clinics in Laboratory Medicine 12, no. 2 (1992): 201–16. http://dx.doi.org/10.1016/s0272-2712(18)30513-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kimiz-Gebologlu, Ilgin, Sultan Gulce-Iz, and Cigir Biray-Avci. "Monoclonal antibodies in cancer immunotherapy." Molecular Biology Reports 45, no. 6 (2018): 2935–40. http://dx.doi.org/10.1007/s11033-018-4427-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Druy, Aleksandr, and Svetlana Kuleva. "NEUROBLASTOMA IMMUNOTHERAPY." Problems in oncology 65, no. 2 (2019): 181–87. http://dx.doi.org/10.37469/0507-3758-2019-65-2-181-187.

Full text
Abstract:
The recent data about innate and adaptive immunity against neuroblastoma are described in the article. The era of neuroblastoma immunotherapy started since the evidence of anti-GD2 monoclonal antibodies efficiency. Nowadays monoclonal antibodies against GD2 are introduced into schemes of maintenance therapy for high-risk neuroblastoma patients. Developing of T-cells expressing chimeric antigen receptor (CAR-T cells) directed to membrane antigens is the perspective of neuroblastoma immunotherapy. PD1/PD-L1 blocking antibodies as immune checkpoint inhibitors have the theoretical evidence of pote
APA, Harvard, Vancouver, ISO, and other styles
6

Peake, S. "Monoclonal Antibodies—Immunotherapy for the Critically Ill." Anaesthesia and Intensive Care 21, no. 6 (1993): 739–51. http://dx.doi.org/10.1177/0310057x9302100602.

Full text
Abstract:
Monoclonal antibodies (mAb) have revolutionised many areas of medicine, particularly research and diagnostics. Murine, human and humanised mAb have all been developed. The most important clinical applications to date have been in the fields of transplantation and oncology. Experimental and limited clinical trials suggest mAb are emerging as a new therapeutic strategy in the critically ill. Antibodies against a variety of bacteria or their products are potentially useful in gram-positive and gram-negative shock. Anti-cytokine and anti-neutrophil adhesion molecule mAb may be effective not only i
APA, Harvard, Vancouver, ISO, and other styles
7

Cai, Xiao‐Jun, Zai‐Wang Li, Jian‐Ying Xi, et al. "Myasthenia gravis and specific immunotherapy: monoclonal antibodies." Annals of the New York Academy of Sciences 1452, no. 1 (2019): 18–33. http://dx.doi.org/10.1111/nyas.14195.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Weiner, Louis M., Rishi Surana, and Shangzi Wang. "Monoclonal antibodies: versatile platforms for cancer immunotherapy." Nature Reviews Immunology 10, no. 5 (2010): 317–27. http://dx.doi.org/10.1038/nri2744.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Douillard, J. Y., B. Le Mevel, C. Curtet, J. Vignoud, J. F. Chatal, and H. Koprowski. "Immunotherapy of gastrointestinal cancer with monoclonal antibodies." Medical Oncology and Tumor Pharmacotherapy 3, no. 3-4 (1986): 141–46. http://dx.doi.org/10.1007/bf02934989.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Steffens, Thomas A., Dean F. Bajorin, and Alan N. Houghton. "Immunotherapy with monoclonal antibodies in metastatic melanoma." World Journal of Surgery 16, no. 2 (1992): 261–69. http://dx.doi.org/10.1007/bf02071530.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Monoclonal antibodies ; Immunotherapy"

1

Thomas, Myles Duncan. "Production and characterisation of novel human monoclonal antibodies against malignant melanoma." Thesis, University of East London, 1995. http://roar.uel.ac.uk/1275/.

Full text
Abstract:
Malignant melanoma is an immunogenic tumour capable of inducing a humoral immune response, as shown by tumour-reactive serum antibody in patients. Lack of effective chemotherapy in association with the immunogenic nature of the malignancy, has stimulated interest in the immunological management of the malignancy by antibody. Many mouse monoclonal antibodies against melanoma antigens have been developed, and some have been shown to induce tumour regression. However, a limitation on the use of mouse monoclonal antibodies in patients is the induction of an immune response against the immunising x
APA, Harvard, Vancouver, ISO, and other styles
2

Saxena, Abhishek. "Construction of immune scFv M13 phage display library and isolation of anti-glycan monoclonal antibodies." Thesis, University of Aberdeen, 2013. http://digitool.abdn.ac.uk:80/webclient/DeliveryManager?pid=203295.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sandin, Linda. "Immunomodulatory Therapy of Solid Tumors : With a Focus on Monoclonal Antibodies." Doctoral thesis, Uppsala universitet, Klinisk immunologi, 2013. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-210080.

Full text
Abstract:
Cancer, historically considered a genetic disease, is currently acknowledged to affect the whole body. Our immune system is one key player that can elicit a response against malignant cells but can also promote tumorigenesis. Tumors avoid immune recognition by creating a suppressive microenvironment and inducing tolerance. T-cells are regarded a major effector cell type in tumor immunotherapy. An important ”switch” needed for T-cell activation involves so-called costimulatory and coinhibitory receptors. In this thesis, experimental tumor models were used to investigate the potential of immunom
APA, Harvard, Vancouver, ISO, and other styles
4

DIAS, CARLA R. de B. R. "Estudo comparativo da marcacao do anticorpo anti-CD20 com sup(188)Re." reponame:Repositório Institucional do IPEN, 2010. http://repositorio.ipen.br:8080/xmlui/handle/123456789/9502.

Full text
Abstract:
Made available in DSpace on 2014-10-09T12:27:22Z (GMT). No. of bitstreams: 0<br>Made available in DSpace on 2014-10-09T14:06:35Z (GMT). No. of bitstreams: 0<br>Tese (Doutoramento)<br>IPEN/T<br>Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP
APA, Harvard, Vancouver, ISO, and other styles
5

Beckwith, Kyle Addison. "Novel Immunotherapeutic Strategies for Chronic Lymphocytic Leukemia." The Ohio State University, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=osu1461203257.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Brunel, Simon. "Immunothérapie du cancer par administration d’anticorps monoclonaux anti-HVEM ou anti-ICOS chez la souris humanisée : potentiel thérapeutique et effets immunologiques." Thesis, Paris 6, 2017. http://www.theses.fr/2017PA066215.

Full text
Abstract:
Un nouveau couple de récepteurs de co-signalisation (BTLA/HVEM) a récemment été proposé comme un acteur important dans l’échappement tumoral. L'expression d’HVEM a été identifiée dans la plupart des cancers. Son niveau expression est inversement corrélé avec la survie des patients. L'expression d’HVEM par des cellules tumorales pourrait inhiber la réponse immunitaire à travers BTLA exprimé par les lymphocytes T.Ainsi, dans notre travail, des anticorps monoclonaux (mAb) ciblant HVEM ont été évalués dans un modèle de souris NSG greffées avec des lymphocytes T et des tumeurs humaines. Nous avons
APA, Harvard, Vancouver, ISO, and other styles
7

Rossmann, Eva D. "Targets for immune mediated killing of tumor cells and T cell functions in B-CLL /." Stockholm, 2003. http://diss.kib.ki.se/2003/91-7349-622-7/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mendes, Priscila Fraga Penteado [UNIFESP]. "Identificação, por anticorpo monoclonal, de proteína de 230 kDa relacionada com malignidade em melanoma murino." Universidade Federal de São Paulo (UNIFESP), 2006. http://repositorio.unifesp.br/handle/11600/9703.

Full text
Abstract:
Made available in DSpace on 2015-07-22T20:50:19Z (GMT). No. of bitstreams: 0 Previous issue date: 2006-12-31<br>Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)<br>Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)<br>Melanomas se destacam entre os tumores sólidos por apresentar alto potencial de malignidade e incidência crescente, especialmente entre indivíduos jovens. Identificação de marcadores moleculares em melanomas é de enorme interesse para uso clínico e para estudos relacionados ao seu desenvolvimento. A linhagem de melanoma murino B16 tem sido
APA, Harvard, Vancouver, ISO, and other styles
9

Gustafsson, Liljefors Maria. "Immunotherapy with the anti-EpCAM monoclonal antibody and cytokines in patients with colorectal cancer : a clinical and experimental study /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-499-6/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Javidipoor, Moossa. "Production and Characterization of Monoclonal Antibodies Against Murine P388D1 Leukemia Cells for Evaluation of Immunotherapy in Tumor Bearing DBA/2 Mice." NSUWorks, 1986. http://nsuworks.nova.edu/occ_stuetd/59.

Full text
Abstract:
The objective of these studies was to produce monoclonal antibodies against P388Dl cells, a lymphocytic leukemia of murine origin, to evaluate the efficacy of immunotherapy in tumor bearing DBA/2 mice. Hybridomas producing anti-P388Dl MAbs were obtained by fusion between Sp2/0 myeloma and irrununized BALB/c spleen cells. Monoclonal antibodies were screened by enzyme linked immunoabsorbent and radioimmunoassays, and positive hybridomas were cloned and further subcloned by limiting dilution in fluid phase. Four subclones designated G10, C9, C7, and D11 showed significant binding to both solubili
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Monoclonal antibodies ; Immunotherapy"

1

Elder, Melissa. Monoclonal antibodies in cancer therapy: Emerging products and markets. Edited by Heffner Steven and Kalorama Information LLC. Kalorama Information, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dijk, Jeroen van. Renal cell carcinoma: Diagnostic and therapeutic applications of monoclonal antibodies. s.n.], 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Therapeutic antibodies: Methods and protocols. Humana Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Luiten, Rosalie Margaretha. New chimeric monoclonal antibodies against human carcinomas: IgE and bispecific antibody-mediated therapy. University of Leiden, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Cell wars: The immune system's newest weapons against cancer. Farrar, Straus, Giroux, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cell wars: The immune system's newest weapons against cancer. Fromm International Pub. Corp., 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

International Workshop on Monoclonal Antibodies and Breast Cancer (3rd 1988 San Francisco, Calif.). Breast cancer immunodiagnosis and immunotherapy. Plenum Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

International Congress on Hormones and Cancer. (3rd 1987 Hamburg, Germany). Immunotherapy and -scintigraphy of tumors with monoclonal antibodies: Satellite-Symposium, 3rd International Congress on Hormones and Cancer, Hamburg, September 1987. Edited by Epenetos A. A, Oberhausen E, and Reisfeld Ralph A. W. Zuckschwerdt Verlag, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gray, Lynn. Dynamic antibody industry, including polyclonals and monoclonals. Business Communications Co., 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

International Workshop on Monoclonal Antibodies and Breast Cancer (4th 1990 San Francisco, Calif.). Breast epithelial antigens: Molecular biology to clinical applications. Plenum Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Monoclonal antibodies ; Immunotherapy"

1

Bell, A. J. "Antilymphocyte Antibodies: Polyclonal and Monoclonal." In Immunotherapy of Disease. Springer Netherlands, 1989. http://dx.doi.org/10.1007/978-94-009-1844-3_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Barth, Matthew J., Jessica Hochberg, Nader Kim El-Mallawany, and Mitchell S. Cairo. "Monoclonal Antibodies Targeting Hematological Malignancies." In Immunotherapy for Pediatric Malignancies. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43486-5_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zarnani, Amir-Hassan, Mahmood Bozorgmehr, Mahdi Shabani, Leila Barzegar-Yarmohammadi, Fatemeh Ghaemimanesh, and Mahmood Jeddi-Tehrani. "Monoclonal Antibodies for Cancer Immunotherapy." In Cancer Immunology. Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-44946-2_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zarnani, Amir-Hassan, Davood Jafari, Mahmood Bozorgmehr, et al. "Monoclonal Antibodies for Cancer Immunotherapy." In Cancer Immunology. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-50287-4_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Masuho, Yasuhiko, Yoh-Ichi Matsumoto, Tohru Sugano, Takami Tomiyama, Satoshi Sasaki, and Tamotsu Koyama. "Development of a Human Monoclonal Antibody against Cytomegalovirus with the Aim of a Passive Immunotherapy." In Therapeutic Monoclonal Antibodies. Palgrave Macmillan UK, 1990. http://dx.doi.org/10.1007/978-1-349-11894-6_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Minard-Colin, Véronique. "Monoclonal Antibodies Targeting the Immune System." In Immunotherapy for Pediatric Malignancies. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43486-5_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Chatterjee, M., K. A. Foon, and H. Kohler. "Anti-idiotypic Monoclonal Antibodies: Novel Approach to Immunotherapy." In The Pharmacology of Monoclonal Antibodies. Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78432-3_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lode, Holger N. "Monoclonal Antibodies Directly Targeting Antigens on Solid Tumours." In Immunotherapy for Pediatric Malignancies. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-43486-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Perrot-Applanat, Martine, Jean-François Prud’homme, Mai-Thu Vu Hai, André Jolivet, Frédéric Lorenzo, and Edwin Milgrom. "Monoclonal Antibodies Against Steroid Receptors and Steroid-Induced Proteins." In Breast Cancer Immunodiagnosis and Immunotherapy. Springer US, 1989. http://dx.doi.org/10.1007/978-1-4757-1296-4_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hack, C. Erik. "Monitoring of immunotherapy with cytokines or monoclonal antibodies." In Animal Cell Technology: Developments Towards the 21st Century. Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0437-1_155.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Monoclonal antibodies ; Immunotherapy"

1

Guo, Jun, Yu Xiao, Ramesh B. Lyer, et al. "Abstract 2783: Empowering therapeutic monoclonal antibodies with IFN-alpha for cancer immunotherapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-2783.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hall, Frederick L., Sant P. Chawla, Neal S. Chawla, and Erlinda M. Gordon. "Abstract 2203: Targeting monoclonal antibodies to the tumor microenvironment for cancer immunotherapy." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-2203.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dubuisson, Agathe. "Abstract B009: New development of monoclonal antibodies targeting TRAIL agonist receptors." In Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-b009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Willis, Sharon. "Abstract 1220: High-resolution epitope mapping differentiates monoclonal antibodies in the crowded cancer immunotherapy space." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Willis, Sharon. "Abstract 1220: High-resolution epitope mapping differentiates monoclonal antibodies in the crowded cancer immunotherapy space." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pyrzynska, Beata, Abdessamad Zerrouqi, Michal Dwojak, et al. "Abstract B17: FOXO1 is transcriptional regulator of malignant B-cell surface antigen CD20, the target for therapeutic monoclonal antibodies." In Abstracts: AACR Special Conference on Tumor Immunology and Immunotherapy; October 1-4, 2017; Boston, MA. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/2326-6074.tumimm17-b17.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Sánchez-Paulete, Alfonso R., Francisco J. Cueto, María Martínez-López, et al. "Abstract 4908: Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires Batf3-dependent dendritic cells." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-4908.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tang, Jun, Laura Pearce, Jill O'Donnell-Tormey, and Vanessa M. Hubbard-Lucey. "Abstract A019: Longitudinal analysis of the landscape of cancer trials testing anti-PD-1/L1 monoclonal antibodies." In Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-a019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jun, H. Toni, Patricia A. McNeeley, Andrew Lassen, et al. "Abstract LB-266: Generation of antagonistic anti-TIM-3 and anti-LAG-3 monoclonal antibodies for potential novel immunotherapy combinations." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-lb-266.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Hooren, Luuk van, Linda Sandin, Igor Moskalev, et al. "Abstract B103: Intralesional administration of CTLA-4 blocking monoclonal antibodies as a means to optimize bladder cancer therapy." In Abstracts: Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 25-28, 2016; New York, NY. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/2326-6066.imm2016-b103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Monoclonal antibodies ; Immunotherapy' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography